Omalizumab is a recombinant DNA derived humanized IgG 1k monoclonal antibody that specifically binds to free human IgE in the blood.
Adults and children aged 6yearsand above.
Confirmed IgE dependent allergic asthma , when serum IgE levels are between 30-700. Not indicated for higher serum IgE levels.
Severe uncontrolled asthma despite optimal pharmacological and non pharmacological management (including immunotherapy) and appropriate allergen avoidance.
Treatment response should be assessed globally. If no response within 4 months of initiating treatment, unlikely that further administration will be beneficial.
Omalizumab is administered subcutaneously once every 2 to 4 weeks. The dosing schedule is according to the serum IgE level and body weight of the patient. Extremely expensive, marketed by Novartis. Consult a pulmnologist or an allergist for treatment.